Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A6 | Q3KNW5 | 2/20 | 1.00 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 1.00 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 1.00 |
| ▸ | METAP2 | P50579 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | GPR27 | Q9NS67 | 10/20 | 0.58 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CCR9 | P51686 | 1/20 | 0.54 |
| ▸ | FLT1 | P17948 | 2/20 | 0.53 |
| ▸ | FLT4 | P35916 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7126120 | 0.99 | SLC10A6 (0.98) | SLC10A6SLC10A2SLC10A1METAP2KMT2A | |
| SCHEMBL5115455 | 0.94 | SLC10A6 (0.88) | SLC10A6SLC10A2SLC10A1METAP2KMT2A | |
| SCHEMBL6861824 | 0.93 | SLC10A6 (0.87) | SLC10A6SLC10A2SLC10A1METAP2KMT2A | |
| SCHEMBL7116008 | 0.92 | SLC10A6 (0.85) | SLC10A6SLC10A2SLC10A1METAP2KMT2A | |
| SCHEMBL7118571 | 0.92 | SLC10A6 (0.85) | SLC10A6SLC10A2SLC10A1METAP2KMT2A | |
| SCHEMBL5597977 | 0.91 | SLC10A6 (0.83) | SLC10A6SLC10A2SLC10A1METAP2KMT2A | |
| SCHEMBL6754585 | 0.90 | SLC10A6 (0.81) | SLC10A6SLC10A2SLC10A1METAP2KMT2A | |
| SCHEMBL7208184 | 0.86 | SLC10A6 (0.76) | SLC10A6SLC10A2SLC10A1METAP2KMT2A | |
| SCHEMBL30777866 | 0.86 | SLC10A6 (0.75) | SLC10A6SLC10A2SLC10A1METAP2KMT2A | |
| SCHEMBL27089455 | 0.86 | SLC10A6 (0.75) | SLC10A6SLC10A2SLC10A1METAP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167180-A1 | Methods for anti-tumor therapy | COMPASS PHARMACEUTICALS, LLC | 2004-08-26 | — | — | US | claimed |
| US-6716879-B2 | ADMINISTERING AN EFFECTIVE AMOUNT OF SULFONYLAMINO-SUBSTITUTED N-ARYL- OR HETEROACRYL OR ALKYL OR CYCLOALKYLCARBOXAMIDE DERIVATIVES OR SALTS, ESTERS, AMIDES OR PRODRUG TO TREAT TUMOR | COMPASS PHARMACEUTICALS, LLC | 2004-04-06 | — | — | US | claimed |
| EP-1317260-A2 | METHODS FOR TREATING TUMORS USING SULFONYL COMPOUNDS | Signature Bioscience, Inc. (US) | 2003-06-11 | — | — | EP | claimed |
| US-20020082243-A1 | Methods for anti-tumor therapy | PHOENIX ONCOLOGY, LLC | 2002-06-27 | — | — | US | claimed |
| WO-2002017897-A2 | METHODS FOR TREATING TUMORS USING SULFONYL COMPOUNDS | PRIMECYTE, INC. (US) | 2002-03-07 | — | — | WO | claimed |
| EP-1317260-A2 | METHODS FOR TREATING TUMORS USING SULFONYL COMPOUNDS | Signature Bioscience, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002017897-A2 | METHODS FOR TREATING TUMORS USING SULFONYL COMPOUNDS | PRIMECYTE, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082243-A1 | Methods for anti-tumor therapy | HCCS, PAICS, TP53 | SLC10A6 1719/4885SLC10A2 846/4885SLC10A1 941/4885 |
| US-20040167180-A1 | Methods for anti-tumor therapy | HCCS, PAICS, TP53 | SLC10A6 1719/4885SLC10A2 846/4885SLC10A1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.